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Abstract 
Regulation of the expression of GPCR fatty acid receptor genes has been examined in human 
adipocytes differentiated in culture. TNFα and IL-1β induced a marked reduction in GPR120 
expression, mRNA level falling 17-fold at 24h in adipocytes incubated with TNFα. In contrast, 
GPR84 mRNA was dramatically increased by these cytokines (>500-fold for IL-1β at 4h); 
GPR41 expression was also stimulated. Rosiglitazone did not affect GPR84 expression, but 
GPR120 and GPR41 expression increased. Dexamethasone, insulin, linoleic and docosahexaenoic 
acids, and TUG891 (GPR120 agonist) had little effect on GPR120 and GPR84 expression. 
TUG891 did not attenuate the pro-inflammatory actions of TNFα and IL-1β. Docosahexaenoic 
acid slightly countered the actions of IL-1β on CCL2, IL6 and ADIPOQ expression, though not 
on secretion of these adipokines. GPR120 and GP84 gene expression in human adipocytes is 
highly sensitive to pro-inflammatory mediators; the inflammation-induced inhibition of GPR120 
expression may compromise the anti-inflammatory action of GPR120 agonists. 
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Introduction 
Several members of the extended family of G-protein-coupled receptors (GPCR) are specific 
sensors/receptors for fatty acids, each of which is selective for different types of fatty acid. 
GPR40 (also known as FFAR1) is activated by saturated and unsaturated medium and long chain 
fatty acids (C8-C22) with GPR41 (FFAR3) and GPR43 (FFAR2) being receptors for short chain 
fatty acids (C1-C6) (Milligan et al., 2014; Watterson et al., 2014; Ulven & Christiansen, 2015). 
GPR84 (EX33) is activated primarily by medium chain fatty acids (C9 to C14 are the most 
potent), while GPR120 (FFAR4) is considered as a receptor for n-3 polyunsaturated fatty acids 
(PUFA), although it is also activated by medium and long chain fatty acids (Oh et al., 2010; 
Milligan et al., 2014; Watterson et al., 2014). These GPCRs have been linked to a range of 
metabolic effects, activation of GPR40, for example, leading to the stimulation of glucose-
dependent insulin secretion by pancreatic β cells (Itoh et al., 2003), while activation of GPR43 by 
short chain fatty acids stimulates the release of leptin from adipocytes and of GLP-1 from 
colonic cells (Zaibi et al., 2010; Tolhurst et al., 2012).  
GPR84, which is the least studied of the GPCR fatty acid sensors, is reported to be a pro-
inflammatory receptor, activation by medium chain fatty acids resulting in chemotaxis and 
cytokine production by macrophages (Suzuki et al., 2013). Activation of GPR120 by n-3 PUFA, 
on the other hand, has been linked to the insulin-sensitising and anti-inflammatory actions of 
these fatty acids, particularly in relation to obesity (Oh et al., 2010; Oh & Olefsky, 2012; Ulven & 
Christiansen, 2015; Moniri, 2016). GPR120 knockout mice become obese on a high fat diet and 
exhibit multiple metabolic disorders, including insulin resistance associated with reduced insulin 
signalling and enhanced inflammation in white adipose tissue (Ichimura et al., 2012). Other 
functions attributed to GPR120 in adipose tissue include the promotion of adipogenesis (Song et 
al., 2016) and the stimulation of VEGF-A production by mature adipocytes (Hasan et al., 2015). 
Each of the GPCRs for fatty acids exhibit selective tissue and cellular distribution in their 
expression. The GPR120 gene is widely expressed, but expression is particularly evident in 
adipose tissue, both in adipocytes themselves and in M1 and M2 macrophages (Oh et al., 2010). 
GPR84 is also expressed in adipocytes, as well as in leukocytes and other immune cells (Wang et 
al., 2006; Nagasaki et al., 2012). GPR84 expression in monocytes/macrophages has been shown 
to be markedly induced by lipopolysaccharide (Wang et al., 2006), while in adipocytes both 
macrophage secretions and TNFα stimulate expression (Nagasaki et al., 2012; Trayhurn & 
Denyer, 2012). In contrast, macrophage secretions appear to down-regulate GPR120 expression 
(Trayhurn & Denyer, 2012). These observations suggest that GPR84 and GPR120 are intimately 
connected to the inflammatory response in adipose tissue which is evident in obesity, the obese 
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state being characterised by chronic inflammation in the tissue (Rajala & Scherer, 2003; Trayhurn 
& Wood, 2004; Hotamisligil, 2006). Adipose tissue inflammation is widely considered to underlie 
the development of several obesity-associated disorders, particularly insulin resistance and the 
metabolic syndrome (Hotamisligil, 2006; Rosen & Spiegelman, 2006; Bluher, 2009). 
The aim of the present study was: (i) to examine the regulation of GPR120 and GPR84 
expression in human adipocytes by a range of factors, both pro-inflammatory and anti-
inflammatory, and including GPR120 agonists; (ii) to examine the effect of GPR120 agonists, 
synthetic and natural, on the inflammatory response induced by TNFα and IL-1β in human fat 
cells. The results demonstrate that both TNFα and IL-1β markedly stimulate the expression of 
GPR84, but inhibit GPR120 expression, and that agonists to GPR120 have little or no effect on 
the stimulation of inflammation by these cytokines in human adipocytes.   
  
Materials and methods 
Adipocyte cell culture 
Human fibroblastic pre-adipocytes were purchased from PromoCell (Germany; Catalogue #C-
12730, Lots #400Z008.1 and 404Z027.2), together with proprietary cell culture media. The pre-
adipocytes were isolated from the subcutaneous adipose tissue of Caucasian females (aged 29 and 
46 years). As previously described, the pre-adipocytes were plated into 12-well plates (5,000 
cells/cm2), cultured to confluence, differentiated into adipocytes and then further cultured for up 
to 14 days (Alomar et al., 2015). In outline, the pre-adipocytes were first cultured in a growth 
medium containing 5% foetal calf serum, epidermal growth factor (10 ng/ml), hydrocortisone (1 
μg/ml) and heparin (90 μg/ml). They were then transferred to a differentiation medium (without 
foetal calf serum) for 72 h, this medium containing IBMX (44 μg/ml), thyroxine (9 ng/ml), 
dexamethasone (400 ng/ml), insulin (0.5 μg/ml) and the PPARγ agonist rosiglitazone (3 μg/ml). 
The differentiating cells were finally incubated in a nutrition medium which contained 3% foetal 
calf serum, dexamethasone (400 ng/ml) and insulin (0.5 μg/ml); this growth medium was 
changed every 2-3 days. The differentiated adipocytes were used at between 12 and 14 days after 
differentiation was induced, by which time they contained multiple lipid droplets. 
 To assess the effects on GPCR gene expression, the fat cells were incubated for either 4 or 
24 h with one of the following agents: human recombinant IL-1β (0.5 or 2 ng/ml: Sigma, UK), 
TNFα (5 and 100 ng/ml; Sigma, UK), rosiglitazone (0.1 and 1 µM; Sigma, UK), dexamethasone 
(2 and 20 nM; Sigma, UK ), insulin (1 and 20 nM; Sigma, UK) or TUG891 (0.5 and 10 µM;  
University of Southern Denmark, Denmark). Control cells received vehicle. In studies 
investigating the effects of insulin and dexamethasone, these hormones were removed from the 
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culture medium 24 h before the start of the experiment (and were absent from the control cells). 
For experiments with the fatty acids linoleic acid and docosahexaenoic acid (DHA), two 
concentrations were used; 25 and 100 μM for DHA, and 50 and 200 μM for linoleic acid. The 
fatty acids were added to the nutrition medium which was supplemented with 0.3% bovine serum 
albumin. 
At the end of the incubation period, the culture medium was aspirated and stored at -20°C; 
the adipocytes were washed and frozen in TRI Reagent (Sigma, UK) and stored at -80oC. A total 
of 3-6 individual sets of cells was taken for each experimental group. 
RNA extraction and real-time PCR 
The adipocytes were thawed on ice, homogenised in the TRI Reagent in which they had been 
stored and total RNA extracted using an RNeasy Micro Kit (Qiagen, UK). The purity of the 
RNA was close to 2.0, based on the 260/280 nm and 260/230 nm ratios (NanoDrop 1000; 
Wilmington, USA). The RNA Integrity Number (Agilent 2100 Bioanalyser; Agilent Technologies, 
Germany) was approximately 10.  
The total RNA was DNAse-treated with a TURBO-DNA-freeTM kit (Ambion, Life 
TechnologiesTM, USA) and 0.8-1.6 μg was reverse transcribed using Taqman® reverse 
transcription reagents (InvitrogenTM, Applied Biosystems, UK). Between 60 and 80 ng of cDNA 
was taken for real-time PCR which was performed in triplicates using Gene Expression Master 
Mix and TaqMan® Gene Assays consisting of specific Taqman® probes (Applied Biosystems®, 
Life TechnologiesTM, USA). Probes were obtained for the human GPR40 (Hs03045166_s1), 
GPR41 (Hs02519193_g1), GPR43 (Hs00271142_s1), GPR84 (Hs01874713_s1), GPR120 
(Hs00699184_m1), CCL2 (Hs00234140_m1), IL1B (Hs01555410_m1), IL6 (Hs00985639_m1), 
IL16 (Hs00189606_m1) and ADIPOQ (Hs00605917_m1) genes; probes were also obtained for 
ACTB (-actin; Hs99999903_m1) as the control gene. PCR reactions were set up in duplex 
format where the FAM-labelled Taqman® probe for the gene of interest was mixed with the VIC-
labelled Taqman® probe for ACTB.  
PCR amplification was performed using an ABI real-time PCR detection system (ABI 
StepOneplusTM, Applied Biosystems®, USA) with a two-step thermal cycling: 95C for 10 min, 
followed by 40 cycles of 95C for 15sec and 60C for 1 min. The data were analysed by the 
comparative 2-ΔΔCt method (Livak & Schmittgen, 2001) and expressed as fold-changes in the 
target gene (normalized to ACTB as the reference gene) in treated adipocytes and related to the 
expression of the control adipocytes (normalised to the mRNA level in the control cells = 1.0). 
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PCR arrays 
PCR arrays were performed essentially according to the manufacturer’s instructions, as described 
previously (Alomar et al., 2015; Kepczynska et al., 2017). Extracted RNA was DNAse-treated, 
reverse transcribed using a RT2 First Strand Kit (Qiagen, UK) and then screened with a RT2 
Profiler PCR array for 84 Human Cytokine and Chemokine genes (Qiagen; Catalogue #PAHS-
150ZC-24). PCR amplification was performed by real-time PCR (ABI StepOneplus) with two-
step thermal cycling using the following protocol; 95oC for 10 min, and then 40 cycles of 95oC 
for 15 sec and 60oC for 1 min. The data were analysed by the comparative 2-ΔΔCt method (Livak 
& Schmittgen, 2001) and expressed as fold-changes in the target gene normalised to the reference 
genes (ACTB, B2M, GAPDH, HPRT, RLPO) for the adipocytes treated with TNFα and related 
to the expression level in the control cells. 
Protein measurements 
The concentration of the adipokines IL-6, IL-16, MCP-1 (encoded by CCL2) and adiponectin 
was measured in the medium using MSD immunoassays (Meso Scale Discovery, USA); these 
assays enable the rapid and sensitive measurement of specific proteins in small sample volumes. 
Before analysis, the media were centrifuged to remove any cell debris. Plates were pre-coated 
with antibodies on independent, discrete spots and the assay then performed essentially 
according to the manufacturer’s instructions, as described previously (Alomar et al., 2015; Alomar 
et al., 2016). The data was analysed using Proprietary Meso Scale software. The lowest level of 
detection was 0.06 pg/ml for IL-6 (interlot CV <20 %), 2.83 pg/ml for IL-16 (interlot CV <20 
%), 0.09 pg/ml for MCP-1 and 5 pg/ml for adiponectin (mean intraplate CV <20 % for MCP-1 
and adiponectin). 
Statistical analysis 
The statistical significance of differences between groups was assessed by one-way ANOVA with 
Bonferroni post-test (for selected groups) or with Student’s unpaired t test; a value of P<0.05 was 
taken as being statistically significant. 
 
Results 
Regulation of GPR120 and GPR84 gene expression 
In the first set of studies, the effect of a series of hormones and other factors on the expression 
of the GPR120 and GPR84 genes was examined in human adipocytes differentiated in culture 
from fibroblastic pre-adipocytes. The expression of the GPR41 gene was also explored. Both 
acute (4 h) and sustained (24 h) responses were examined, and a low and a high concentration of 
the agent were generally employed, based on previous work (Peeraully et al., 2004; Gao & Bing, 
7 
 
2011; Alomar et al., 2015). The initial studies focused on the effects of the pro-inflammatory 
cytokines TNFα and IL-1β.  
Incubation with TNFα resulted in a dose-dependent reduction in GPR120 mRNA level at 
both 4 and 24 h of treatment (Fig 1A). At 4 h, GPR120 mRNA level fell with the higher dose to 
22% of the control cells, while at 24 h it was reduced to just 6% of controls – a 17-fold 
reduction. In marked contrast to GPR120, there was a major stimulation of GPR84 expression by 
TNFα (Fig 1A), and as with GPR120 this was dose-dependent at both time-points. The increase 
in GPR84 mRNA was greater at 4 than at 24 h, the level being ~200-fold greater relative to the 
controls with the higher dose at 4 h; surprisingly, the 46-fold increase in GPR84 mRNA at 24 h 
with the high dose was not statistically significant due to the considerable variation observed. 
The effect of TNFα on the expression of GPR40, GPR41 and GPR43 was also determined. 
There was a marked stimulation of GPR41 expression at 24 h, the mRNA level being >30-fold 
higher with both the low and high doses of the cytokine (Fig 1A). There was also an increase at 4 
h, albeit much lower, at just 4-fold relative to the control cells (Fig 1A). Modest, but statistically 
significant, increases in GPR40 mRNA level at 4 h (both doses) and at 24 h for the low, though 
not the high, dose of TNFα were evident (results not shown). GPR43 mRNA level was not 
significantly increased by TNFα at 4 h, but there was a significant increase at 24 h and this was 
greater for the low dose (11-fold) than the high (5-fold) (results not shown). 
The effects of IL-1β were examined using a single high concentration, based on previous 
studies on human adipocytes with this cytokine (Alomar et al., 2015). IL-1β had broadly similar 
effects to TNFα, with a reduction in GPR120 mRNA level and an increase in GPR84 mRNA 
(Fig 1B). However, the 2-fold decrease in GPR120 mRNA level in response to IL-1β was less 
than with TNFα and there was no difference between the 4 and 24 h time-points. The effect of 
IL-1β on GPR84 expression was dramatic with the mRNA level being >500-fold higher at 4 h 
compared with the control cells. This considerable effect of IL-1β was relatively transitory, with 
the increase in mRNA level falling sharply by 24 h to 15.7-fold relative to the controls. There was 
also a marked stimulation of GPR41 expression in response to IL-1β, the mRNA level being 16-
fold and 37-fold higher than in the control cells at 4 and 24 h, respectively (Fig 1B). 
Incubation with rosiglitazone led to a significant increase in GPR120 gene expression at 
both 4 and 24 h of treatment. With the highest dose of rosiglitazone, there was a nearly 8-fold 
increase in GPR120 mRNA level at 24 h (Fig. 2A). GPR41 expression was also stimulated by 
rosiglitazone, paralleling the response of GPR120; the high dose of the PPARγ agonist resulted in 
a 10-fold increase in GPR41 mRNA level at 24 h (Fig. 2A). In contrast to GPR120 and GPR41, 
rosiglitazone had no effect on GPR84 expression (Fig. 2A).  
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Insulin had no significant effect on GPR120 gene expression following 24 h of treatment, 
but there was a small stimulation with the higher dose at 4 h, mRNA level being increased 4.7-
fold relative to the controls (Fig. 2B). There was no significant effect of insulin on either GPR84 
(Fig 2B) or GPR41 expression (result not shown). Dexamethasone, with its anti-inflammatory 
action, was without effect on GPR120 mRNA level, irrespective of the dose or incubation time 
(Fig 2C). There was also no significant effect of the glucocorticoid on GPR84 mRNA, except at 
24 h with the high dose where there was a small decrease (to 35% of the controls). There was 
also little effect of dexamethasone on GPR41 expression, except for a small though statistically 
significant, increase in mRNA level at 4 h with the higher dose (result not shown). 
In the next set of experiments, the effects of two PUFAs were examined. The adipocytes 
were incubated with two different concentration of the fatty acids, as in the other studies. There 
was no significant effect of linoleic acid, an n-6 PUFA, on GPR120, GPR84 or GPR41 expression 
at either 4 or 24 h with both of the concentrations employed (Fig 3A). DHA, an n-3 PUFA 
which is a natural ligand for GPR120 (Milligan et al., 2015; Ulven & Christiansen, 2015; Calder, 
2016), also had no significant effect on GPR84 or GPR41 mRNA level at 4 or 24 h, and nor was 
there any effect on GPR120 mRNA level at 4 h (Fig 3B). There was, however, a small (2.2-fold), 
but statistically significant, increase at 24 h with the higher concentration of DHA (Fig 3B). 
The final agent examined was TUG891, a synthetic agonist to GPR120 (Milligan et al., 
2015; Gozal et al., 2016). Treatment with TUG891 had no significant effect on GPR120 gene 
expression, nor on the expression of GPR84 and GPR41; this was the case at 4 and 24 h of 
treatment and with both low and high doses of the agonist (Fig. 3C) 
Effect of TUG891 on the inflammatory response in adipocytes 
In view of the strong down-regulation of GPR120 expression by TNFα and IL-1β, in the next 
studies the effect of GPR120 agonists on the inflammatory response evoked by these pro-
inflammatory cytokines was examined. In the first experiment, adipocytes were treated with 
either TNFα or IL-1β in the presence and absence of TUG891 for 4 h to assess the effect of the 
agonist on the acute response to the pro-inflammatory cytokines. PCR arrays containing probes 
for 84 cytokine and chemokine genes were used to examine the response to TNFα and whether 
this was attenuated by TUG891. The results in Table 1 indicate that TNFα had a powerful 
stimulatory effect on the expression of a substantial number of cytokine and chemokine genes 
(the full gene list is given in Appendix A). A total of 37 genes of those probed by the arrays 
exhibited increased expression (Appendix A); the mRNA level of 8 genes increased >100-fold 
with a further 10 exhibiting >10-fold increases (Table 1). The most strongly up-regulated genes 
were CXCL10, CCL5 and CCL1, the mRNA levels of which were 907-, 438- and 395-fold 
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higher, respectively, than in the control untreated adipocytes. The expression of a small number 
of genes was inhibited by TNFα, with IL11 and IL16 (8.8-fold reduction in mRNA level) being 
the most strongly down-regulated (Table 1). 
 In contrast to TNFα, incubation with TUG891 had little effect on cytokine and chemokine 
expression (Table 1). IL15 was the only gene for which there was a statistically significant 
reduction in mRNA level (to 68% of control cells). There were, however, significant increases in 
mRNA for 19 genes, but for all but two of these the increase in level was just 1.1 to 2-fold, with 
the highest (TNFSF11) being 3.5-fold. When the adipocytes were incubated with TNFα and 
TUG891 together, the changes in mRNA level relative to the untreated cells were very similar to 
those with TNFα alone, both in terms of the scale of change and the rank order of the 
responsive genes (Table 1). For example, as with TNFα on its own CXCL10 and CCL5 were the 
most strongly up-regulated genes with the combination of TNFα+TUG891, while IL16 was the 
most strongly down-regulated. 
The impact of TUG891 on the response to TNFα is demonstrated most clearly by 
comparing mRNA levels in the TNFα+TUG891 group compared with TNFα alone. Table 1 
shows that the presence of TUG891 led to a reduction in the mRNA level for only three genes, 
there being no significant change for >70% of the genes probed by the arrays. The three genes 
where the TNFα-stimulated expression was significantly inhibited by TUG891 were CXCL10, 
TGFB2 and TNFSF10, but in each case the decrease in the mRNA level was <30%; the fall in 
CXCL10 mRNA level in the presence of TUG891 was just 18%. Paradoxically, rather than 
substantial decreases there was a statistically significant, albeit small, increase in mRNA level for 
17 genes in the TUG891+TNFα group compared with TNFα alone; however, most of these 
changes resulted in increases of <1.5-fold with the highest (IL1RN) being 1.9-fold. 
 A similar study was conducted with adipocytes incubated with IL-1β in the presence and 
absence of TUG891, and in view of the results with TNFα the expression of selected genes was 
examined rather than multiple genes through PCR arrays. While treatment with IL-1β resulted in 
a substantial increase in CCL2, IL-1β and IL-6 mRNA levels, the addition of TUG891 did not 
attenuate the response (Fig 4). Similarly, the down-regulation of ADIPOQ expression by IL-1β 
was not modified by TUG891. The presence of TUG891 also did not attenuate the increase in 
GPR84 expression stimulated by IL-1β, but paradoxically it accentuated the reduction in GPR120 
mRNA level induced by the cytokine (Fig 5A).   
Analysis of selected inflammation-related adipokines in the medium showed that the 
presence of TUG891 did not alter the level of the secreted proteins evident with IL-1β alone; 
there was no difference between the IL-1β+TUG891 and IL-1β groups in the amounts of IL-6, 
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IL-16, MCP-1 or adiponectin in the medium (Fig 6A). Similarly, with the adipocytes treated with 
TNFα, the presence of TUG891 did not alter the quantity of MCP-1, IL-16 and adiponectin 
detected in the medium. In the case of TNFα there was actually a small, but statistically 
significant, increase in the amount of this adipokine released by cells incubated with 
TUG891+TNFα relative to those with TNFα alone (Fig 6B). 
Effect of DHA on IL-1β induced changes in gene expression 
In the final experiment, adipocytes were incubated with DHA as a natural ligand to GPR120, and 
the inflammatory response induced by IL-1β examined in the presence and absence of the fatty 
acid. The adipocytes were incubated for 4 and 24 h in order to assess whether any putative effects 
are acute or chronic; results are, however, shown for 24 h only as no acute effects were evident. 
The presence of DHA did not lead to an attenuation of the increases in IL-6 and IL-1β 
mRNA level induced by IL-1β at either 4 or 24 h (Fig 7). There was, however, a significant 
attenuation of CCL2 gene expression at 24 h (Fig 7). Similarly, at 24 h the presence of DHA 
resulted in an attenuation in the decrease in IL16 and ADIPOQ expression observed with IL-1β 
(Fig 7). Thus, some modest effects of DHA on the inflammatory response induced by the pro-
inflammatory cytokine are apparent. However, the presence of DHA did not have a protective 
effect on the reduction in GPR120 gene expression occurring with IL-1β (Fig 7). There was, in 
contrast, an attenuation by DHA of the IL-1β-induced increase in GPR84 mRNA level (Fig 7). 
As in the studies with TUG891, the effect of DHA on the release of key inflammation-
related adipokines from adipocytes treated with IL-1β was examined. The 24 h samples were 
used in order to assess the consequences of longer-term exposure to the fatty acid and the 
cytokine. The presence of DHA did not result in any changes in the amount of IL-6, IL-16, 
MCP-1 or adiponectin found in the medium (Fig 6C).  
  
Discussion 
The present study demonstrates that several factors influence the expression of the genes 
encoding the major fatty acid receptors/sensors - GPR120, GPR41 and GPR84 - in human 
adipocytes. Major responses were observed following exposure to pro-inflammatory mediators, 
while insulin, the glucocorticoid dexamethasone, and the fatty acids DHA and linoleic acid had 
no, or limited, effects. In a previous report it was noted that incubation of human adipocytes 
with macrophage-conditioned medium (from U937 cells) resulted in a substantial stimulation of 
GPR84 expression, while GPR120 expression was markedly inhibited (Trayhurn & Denyer, 
2012). A substantial up-regulation of GPR84 expression has also been observed in murine 3T3-
L1 adipocytes co-cultured with the RAW264 macrophage cell line (Nagasaki et al., 2012).  
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Macrophage-conditioned medium contains a multiplicity of secretory products from the 
activated immune cells, among the most important of which are the cytokines TNFα and IL-1β. 
GPR120 gene expression was inhibited in the present study by both these cytokines, the 
reduction in mRNA level being particularly marked with TNFα. In contrast, there was a major 
stimulation of GPR84, and to a lesser extent GPR41, expression by both TNFα and IL-1β. 
Stimulation of GPR84 expression in 3T3-L1 and human adipocytes (adipose-derived stromal 
cells) by TNFα has been observed previously, and also in response to lipopolysaccharide 
(Nagasaki et al., 2012). In the present study, the stimulatory effect on GPR84 expression was 
greatest with IL-1β at 4 h, but there was no difference between IL-1β and TNFα in the peak 
effect on GPR41 expression. Differences in the time-course of the response of the two genes 
were apparent, however, with that of GPR84 being greatest at 4 h, with the mRNA level falling 
sharply by 24 h; this effect was particularly evident with IL-1β. In the case of GPR41, gene 
expression was more strongly stimulated at 24 h, and this was most apparent with TNFα.  
Although a signal for GPR41 was consistently observed in the present work using real-time 
PCR, the mRNA was not detected in the study on macrophage-conditioned medium which 
utilised human Oligo microarrays (O’Hara et al., 2009). Studies on murine adipose tissue have 
also reported a lack of GPR41 expression (Zaibi et al., 2010), although some other reports have 
observed clear signals together with functional responses associated with this receptor (Xiong et 
al., 2004; Han et al., 2014). GPR41, for which the main ligands are short chain fatty acids 
(Milligan et al., 2014; Ulven & Christiansen, 2015), is less well-characterised than the other GPCR 
fatty acid receptors, but it was reported to mediate the stimulation of leptin secretion from 
adipocytes by propionate and butyrate (Xiong et al., 2004). Subsequent studies have suggested, 
however, that this role is played by GPR43 rather than GPR41 (Zaibi et al., 2010). 
The individual effects of IL-1β and TNFα suggest that these cytokines are key factors in 
the responses of human adipocytes to macrophage-conditioned medium (Trayhurn & Denyer, 
2012), although the involvement of other macrophage secretions cannot be excluded. The 
inflammatory response appears to be central to the overall regulation of the expression of GPCR 
fatty acid receptor genes, at least in adipocytes, and in the function of the encoded receptors. The 
up-regulation of GPR120 expression by rosiglitazone is also of note in this regard, given the anti-
inflammatory actions associated with the PPARγ receptor.  
GPR84, the primary ligands for which are medium chain fatty acids of carbon chain length 
9-14 (Wang et al., 2006), has been proposed as a pro-inflammatory receptor (Suzuki et al., 2013). 
For example, activation of GPR84 is reported to amplify the production of IL-8 and IL-12 p40 
by lipopolysaccharide in polymorphonuclear leukocytes as well as the production of TNFα in 
12 
 
macrophages (Wang et al., 2006; Suzuki et al., 2013). On this basis, the stimulation of GPR84 
synthesis in human adipocytes by cytokines, derived either from macrophages or from other 
adipocytes, would be predicted to result in an amplification of the inflammatory response in 
adipose tissue. 
GPR120 has been the focus of considerable interest following the report that it is a 
receptor for n-3 PUFAs and mediates their anti-inflammatory and insulin-sensitising actions (Oh 
et al., 2010; Oh & Olefsky, 2012). Medium-chain fatty acids are also ligands for this receptor. 
GPR120 has been implicated in energy balance, loss or dysfunction of the receptor leading to 
obesity in both mice and humans as well as to glucose intolerance and adipose tissue 
inflammation (Ichimura et al., 2012). Other functions in which the receptor is implicated include 
the promotion of GLP-1 secretion from gastrointestinal L- and K- cells, and the regulation of 
adipogenesis (Gotoh et al., 2007; Moniri, 2016). The proposed insulin-sensitising and anti-
inflammatory actions of GPR120 are of particular significance. GPR120 activation enhances 
glucose uptake and the translocation of GLUT4 in 3T3-L1 adipocytes, while in vivo studies have 
demonstrated that diets enriched in n-3 PUFAs lead to a reduction in macrophage infiltration in 
white adipose tissue of mice together with a reduction in the expression of pro-inflammatory 
genes such as IL1B, IL6 and CCL2, effects that are attenuated in GPR120 knockout mice (Oh et 
al., 2010). 
As a consequence of its apparent regulatory function in inflammation and insulin 
sensitivity, GPR120 has been viewed as a therapeutic target in the treatment of insulin resistance, 
type 2 diabetes and the metabolic syndrome (Milligan et al., 2015; Ulven & Christiansen, 2015). 
Natural ligands for the receptor include eicosapentanoic acid, pinolenic acid and DHA 
(Christiansen et al., 2015), while TUG891 and NCG21 are current examples of synthetic ligands 
(Hudson et al., 2013; Milligan et al., 2015; Ulven & Christiansen, 2015). In view of the anti-
inflammatory action associated with GPR120 it appears paradoxical that macrophage secretions, 
and specifically IL-1β and TNFα, lead to an inhibition of its synthesis. This is based on the 
marked inhibitory effects on gene expression; attempts to measure GPR120 protein in human 
adipocytes by Western blotting were unsuccessful (which may reflect low levels in the cells). A 
question of significance is whether the anti-inflammatory actions of n-3 PUFAs are 
compromised, or attenuated, by a loss in GPR120 receptor production under inflammatory 
conditions?  
In the present study, the presence of TUG891 did not inhibit the acute stimulation of the 
expression of cytokine and chemokine genes induced by TNFα, where PCR arrays were 
employed, or by IL-1β when selective genes were examined. The only gene whose expression was 
13 
 
strongly stimulated by TNFα and which exhibited an inhibitory response to the simultaneous 
presence of TUG891 was CXCL10, which encodes the interferon gamma-induced protein 10 
(IP-10), and even this effect was modest. Thus, there was no evidence of a significant anti-
inflammatory effect of the GPR120 ligand in human adipocytes. Previous studies with TUG891 
have indicated that it mimics the effects of GPR120 activation, such as the enhancement of 
glucose uptake by 3T3-L1 cells and inhibition of the release of pro-inflammatory mediators in  
macrophage cell lines (Hudson et al., 2013). In addition, TUG891 has recently been shown to 
significantly reduce inflammation and insulin resistance induced by chronic sleep fragmentation 
in mice (Gozal et al., 2016); the effects on inflammation were, however, based on macrophages 
present in the stromal-vascular fraction of white fat rather than the adipocyte component of the 
tissue.  
DHA, a natural ligand for GPR120, did have some selective, though limited, effect on the 
response of human adipocytes to IL-1β with prolonged incubation. While DHA did not modify 
the IL-1β induced stimulation of IL6 and IL1B expression, there was a distinct attenuation of 
CCL2 expression, indicating that the production of a major chemoattractant (MCP-1) was 
reduced by the GPR120 ligand (in contrast to TUG891). Interestingly, a reversal of the fall in 
ADIPOQ expression induced by IL-1β was also evident in the presence of DHA, implying that 
the n-3 PUFA aided the preservation of adiponectin synthesis. This would be consistent with the 
anti-inflammatory effect of DHA given that adiponectin itself has an anti-inflammatory (Ouchi et 
al., 1999; Yokota et al., 2000), as well as insulin-sensitising, action (Berg et al., 2001; Yamauchi et 
al., 2001). However, DHA did not alter the suppressive effect of IL-1β on the secretion of 
adiponectin into the medium, nor that of IL-6 and IL-16. The amount of these adipokines 
measured in the medium relates, of course, to the total released over the full 24 h incubation 
period, while the measurements of mRNA level reflect the situation pertaining at the 24 h time-
point itself.  
The absence of a strong anti-inflammatory effect of both TUG891 and DHA in human 
adipocytes exposed to IL-1β and TNFα is not consistent with the proposition that n-3 PUFAs 
inhibit inflammation (Calder, 2011; Calder, 2015) and that GPR120 is a key receptor in mediating 
this action (Oh et al., 2010; Oh & Olefsky, 2012). It is possible, of course, that human adipocytes 
are less responsive to both natural and synthetic GPR120 ligands than other cell types, 
particularly macrophages. If this is the case, then one potential explanation is that the amount of 
GPR120 is low in human adipocytes, and as noted above we were unable to successfully measure 
the protein in the human fat cells employed.  
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An intriguing possibility is that the inflammatory response within human adipocytes is not 
significantly attenuated by DHA and other GPR120 receptor ligands since pro-inflammatory 
cytokines, as well as other macrophage- and adipocyte-derived factors, induce a substantial down-
regulation of the synthesis of this receptor. The presence of DHA did not prevent the inhibition 
of GPR120 gene expression induced by IL-1β, so the apparent detrimental effects of an 
inflammatory stimulus on the production of the receptor are not ameliorated by the n-3 PUFA. 
Furthermore, the combination of TUG891 and IL-1β resulted in a greater down-regulation of 
GPR120 expression than with IL-1β alone. DHA (though not TUG891) did, however, attenuate 
the increase in GPR84 expression induced by IL-1β, and since this receptor is considered pro-
inflammatory (Suzuki et al., 2013) the n-3 PUFA did in effect exhibit some anti-inflammatory 
action.  
 
Conclusions 
The regulation of GPR120 and GPR84 expression in human adipocytes is strongly influenced by 
major pro-inflammatory cytokines, with an inhibition of the former and stimulation of the latter. 
In human fat cells, neither a natural nor a synthetic ligand of GPR120 was able to attenuate the 
major inflammatory response stimulated by TNFα or IL-1β, and this may in part be a 
consequence of an inflammation-induced reduction in the expression of the receptor. Adipocytes 
are able to exhibit a substantial inflammatory response (Rajala & Scherer, 2003; Trayhurn & 
Wood, 2004; Trayhurn, 2005), and despite this not being significantly attenuated by GPR120 
agonists, n-3 PUFAs may have an overall anti-inflammatory action in adipose tissue through the 
other cell types within the tissue, especially the macrophages that are recruited in obesity.     
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Table 1. Effect of TNFα and the GPR120 agonist TUG891 on the expression of cytokine and 
chemokines genes in human adipocytes assessed by PCR arrays. 
  
Gene 
 
TNFα cpd to 
control 
(fold-change) 
TUG891 cpd to 
control  
(fold-change) 
TNFα+TUG891 cpd 
to control (fold-
change) 
TNFα+TUG891 
cpd to TNFα (fold-
change) 
  
  
 CXCL10 907*** 0.285 747*** 0.823* 
CCL5 438*** 0.968 461*** 1.05 
CCL1 395*** 1.23 365*** 0.922 
CXCL11 305*** 0.441 267*** 0.875 
CSF2 253*** 2.47* 378*** 1.49*** 
CCL3 207*** 0.619 279*** 1.35 
CCL20 157*** 1.92*** 194*** 1.24* 
CX3CL1 140*** 1.33 121*** 0.863 
CSF3 93.7*** 1.66 135*** 1.44* 
CXCL8 89.2*** 1.37** 98.8*** 1.11* 
TNF 83.9*** 0.695 69.3*** 0.826 
CCL19 59.6*** 0.143 42.2*** 0.708 
IL1B 55.9*** 0.690 63.0*** 1.13 
CCL2 30.8*** 1.13 31.9*** 1.04 
CXCL2 29.1*** 1.41*** 30.6*** 1.05 
CXCL1 25.3*** 1.40** 28.0*** 1.11** 
CCL7 16.8*** 1.73*** 23.3*** 1.39** 
IL6 11.0*** 1.78*** 14.9*** 1.36** 
LIF 8.62*** 1.86** 13.7*** 1.59** 
BMP2 8.24*** 2.31** 14.7*** 1.79** 
IL15 6.69*** 0.682** 6.74*** 1.01 
CXCL5 6.64*** 1.02 8.09*** 1.22** 
TNFRSF11B 3.46*** 1.39** 3.78*** 1.09 
TNFSF11 3.41 3.54* 14.3 4.18 
IL1RN 3.14*** 1.93** 6.03*** 1.92** 
TGFB2 2.37*** 1.13 1.84*** 0.779** 
TNFSF10 1.36** 1.02 0.973 0.713*** 
TNFSF13B 1.36*** 0.985 1.22** 0.896 
IL12A 0.806* 1.37** 1.08 1.34** 
ADIPOQ 0.729* 0.987 0.839 1.15 
SPP1 0.675*** 1.03 0.796* 1.18** 
BMP6 0.552*** 1.23** 0.696*** 1.26* 
IL11 0.226* 1.89* 0.670 2.97 
IL16 0.113*** 1.09 0.246*** 2.18 
 
Differentiated human adipocytes were incubated in the presence or absence of human 
recombinant TNFα (100 ng/ml), with and without TUG891 (10 μM), for 4 h. The expression of 
84 cytokine and chemokine genes was probed using PCR pathway arrays. The results, which are 
for selected genes (the full gene list is given in Appendix A) are expressed as fold-changes in 
mRNA level for each treatment relative to the group to which it is compared, and are the means 
of 6 sets of adipocytes. *P<0.05, **P<0.01, ***P<0.001 compared to control or to TNFα treated 
cells. All other differences are not statistically significant (P>0.05). 
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Legends to Figures 
 
Figure 1. Effect of (A) TNFα and (B) IL-1β on the expression of the GPR120, GPR84 and 
GPR41 genes in human adipocytes. The adipocytes were incubated with TNFα or IL-1β for 
either 4 or 24 h; LD, low dose TNFα (5 ng/ml) and HD, high dose TNFα (100 ng/ml). IL-1β 
was used at a concentration of 2 ng/ml. The results, which are expressed as fold-changes in 
mRNA level in cells treated with TNFα or IL-1β relative to the respective control cells, are 
means + SE (bars) for 4-6 sets of adipocytes. **P<0.01, ***P<0.001 compared with the control 
cells (Con) at the same time point. 
 
Figure 2. Effect of (A) rosiglitazone, (B) insulin and (C) dexamethasone on the expression of the 
GPR120 and GPR84 genes in human adipocytes. Data for GPR41 are also shown in the case of 
rosiglitazone. The adipocytes were incubated with rosiglitazone (LD, low dose = 0.1 μM and 
HD, high dose =1 μM), insulin (LD, low dose = 1 nM; HD, high dose = 20 nM), or 
dexamethasone (LD, low dose = 2 nM; HD, high dose = 20 nM) for either 4 or 24 h The results, 
which are expressed as fold-changes mRNA level in the cells treated with each agent relative to 
the respective control cells, are means + SE (bars) for 2-4 sets of adipocytes. *P<0.05, **P<0.01, 
***P<0.001 compared with the control cells (Con) at the same time point. 
 
Figure 3. Effect of (A) linoleic acid, (B) docosahexaenoic acid and (C) TUG891 on the 
expression of the GPR120 and GPR84 genes in human adipocytes. The adipocytes were 
incubated with linoleic acid (LD, low dose = 50 μM; HD, high dose = 200 μM) or 
docosahexaenoic acid (LD, low dose = 25 μM; HD, high dose = 100 μM), or TUG891 (LD, low 
dose = 500 nM; HD, high dose = 10 μM) for either 4 or 24 h. The results, which are expressed 
as fold-changes in mRNA level in the cells treated with the fatty acid or TUG891 relative to the 
control cells (Con), are means + SE (bars) for 2-4 sets of adipocytes. *P<0.05 compared with the 
control cells at the same time point. 
 
Figure 4. Effect of TUG891 on the changes induced by IL-1β in the expression of the CCL2, 
IL1B, IL6 and ADIPOQ genes in human adipocytes. The adipocytes were incubated with IL-1β 
(0.5 ng/ml), with and without TUG891 (10 μM), for 4 h. mRNA levels were measured by real-
time PCR. The results, which are expressed as fold-changes in the mRNA level in treated cells 
relative to the control cells (Con), are means + SE (bars) for 4-6 sets of adipocytes. ***P<0.001 
compared with the control cells. 
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Figure 5. Effect of (A) TUG891 and (B) docosahexaenoic acid on the changes induced by IL-1β 
in the expression of the GPR120 and GPR84 genes in human adipocytes. The adipocytes were 
incubated with IL-1β (0.5 ng/ml), with and without TUG891 (10 μM) for 4 h, or with and 
without docosahexaenoic acid (100 μM), for 24 h. The results, which are expressed as fold-
changes in the treated cells relative to the control cells (Con), are means + SE (bars) for 4-6 sets 
of adipocytes. *P<0.05, **P<0.01, ***P<0.001 compared with the control cells. ##P<0.01, 
###P<0.001 compared with TUG891 alone; #P<0.05 compared with DHA alone; √√P<0.01 
compared with IL-1β alone. 
 
Figure 6. Release of inflammation-related adipokines from human adipocytes following 
treatment with either IL-1β or TNFα in the presence and absence of a GPR120 agonist. (A) IL-
1β (0.5 ng/ml) + TUG891 (10 μM), (B) TNFα (100 ng/ml) + TUG891 (10 μM) (C) IL-1β + 
docosahexaenoic acid (DHA, 100 μM). The medium was from the adipocytes used in Figs 6, 7 
and 9, and Table 1. The results are means + SE (bars) for 4 sets of adipocytes in each group; 
open bars, cytokine alone; filled bars cytokine + TUG891 or DHA. ***P<0.001 compared with 
the cells incubated without TUG891 (open bars). 
 
Figure 7. Effect of docosahexaenoic (DHA) acid on the changes induced by IL-1β in the 
expression of CCL2, IL1B, IL6 and ADIPOQ) in human adipocytes. The adipocytes were 
incubated with IL-1β (0.5 ng/ml), with and without DHA (100 μM), for 24 h. The results, which 
are expressed as fold-changes in mRNA level in treated cells relative to the control cells (Con), 
are means + SE (bars) for 6 sets of adipocytes. ***P<0.001 compared with the control cells. 
#P<0.05, ##P<0.01, ###P<0.001compared with DHA alone. 
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Table 1.  Effect of TNFα and the GPR120 agonist TUG891 on the expression of cytokine and 
chemokines genes in human adipocytes assessed by PCR arrays. 
  
Gene 
 
TNFα cpd to 
control 
(fold-change) 
TUG891 cpd to 
control  
(fold-change) 
TNFα+TUG891 cpd 
to control (fold-
change) 
TNFα+TUG891 
cpd to TNFα  
(fold-change) 
  
  
 CXCL10 907*** 0.285 747*** 0.823* 
CCL5 438*** 0.968 461*** 1.05 
CCL1 395*** 1.23 365*** 0.922 
CXCL11 305*** 0.441 267*** 0.875 
CSF2 253*** 2.47* 378*** 1.49*** 
CCL3 207*** 0.619 279*** 1.35 
CCL20 157*** 1.92*** 194*** 1.24* 
CX3CL1 140*** 1.33 121*** 0.863 
CSF3 93.7*** 1.66 135*** 1.44* 
CXCL8 89.2*** 1.37** 98.8*** 1.11* 
TNF 83.9*** 0.695 69.3*** 0.826 
CCL19 59.6*** 0.143 42.2*** 0.708 
IL1B 55.9*** 0.690 63.0*** 1.13 
CCL2 30.8*** 1.13 31.9*** 1.04 
CXCL2 29.1*** 1.41*** 30.6*** 1.05 
CXCL1 25.3*** 1.40** 28.0*** 1.11** 
CCL7 16.8*** 1.73*** 23.3*** 1.39** 
IL6 11.0*** 1.78*** 14.9*** 1.36** 
CCL11 9.63*** 0.321 9.44** 0.981 
LIF 8.62*** 1.86** 13.7*** 1.59** 
BMP2 8.24*** 2.31** 14.7*** 1.79** 
IL15 6.69*** 0.682** 6.74*** 1.01 
CXCL5 6.64*** 1.02 8.09*** 1.22** 
CXCL9 6.46* 1.03 3.40 0.527 
CSF1 4.84*** 1.09** 4.87*** 1.01 
LTB 3.91* 0.960 2.28 0.583 
TNFRSF11B 3.46*** 1.39** 3.78*** 1.09 
TNFSF11 3.41 3.54* 14.3 4.18 
IL1RN 3.14*** 1.93** 6.03*** 1.92** 
TGFB2 2.37*** 1.13 1.84*** 0.779** 
IL23A 2.01*** 1.82* 2.11** 1.05 
IL5 1.90 1.14 0.237 0.124 
CCL13 1.47*** 0.958 1.79*** 1.22* 
CNTF 1.37*** 1.21 1.52*** 1.11 
BMP4 1.37 1.14 1.82* 1.33 
TNFSF10 1.36** 1.02 0.973 0.713*** 
VEGFA 1.36** 1.29** 1.68*** 1.23** 
TNFSF13B 1.36*** 0.985 1.22** 0.896 
IL7 1.36*** 0.849 1.43*** 1.05 
PPBP 1.35 1.16 1.10 0.817 
CXCL16 1.31* 1.22 1.24* 0.951 
LTA 1.19 1.12 3.31* 2.79 
IL18 1.08 0.837 1.12 1.04 
MIF 1.01 1.07** 0.960 0.946 
CXCL12 1.00 1.04 1.07 1.06 
GPI 0.964* 1.02 0.990 1.03 
CCL21 0.842 1.37 2.25 2.68 
C5 0.825* 0.886 0.770** 0.933 
IL27 0.808 1.68 1.58 1.95 
IL12A 0.806* 1.37** 1.08 1.34** 
NODAL 0.797 1.49 1.19 1.49 
IL13 0.754 2.39 1.41 1.87 
ADIPOQ 0.729* 0.987 0.839 1.15 
MSTN 0.701 0.939 0.729 1.04 
IL22 0.699* 0.995 1.24 1.77 
SPP1 0.675*** 1.03 0.796* 1.18** 
THPO 0.658 1.21 0.999 1.52* 
IL4 0.656 0.919 1.59 2.42 
IL21 0.643 ND 0.790 1.23 
BMP6 0.552*** 1.23** 0.696*** 1.26* 
IL24 0.515 0.715 0.553 1.08 
IL17F 0.445 0.554 1.08 2.42 
BMP7 0.432 0.394 0.630 1.46 
CCL18 0.419* 0.696 0.743 1.77 
IFNA2 0.405 0.606 1.35 3.32 
CD40LG 0.370 0.880 0.298 0.805 
IL11 0.226* 1.89* 0.670 2.97 
IL16 0.113*** 1.09 0.246*** 2.18 
 
 
Differentiated human adipocytes were incubated in the presence or absence of human 
recombinant TNFα (100 ng/ml), with and without TUG891 (10 μM), for 4 h. The expression of 
84 cytokine and chemokine genes was probed using PCR pathway arrays. The results are 
expressed as fold-changes in mRNA level for each treatment relative to the group to which it is 
compared, and are the means of 6 sets of adipocytes. *P<0.05, **P<0.01, ***P<0.001 compared 
to control or to TNFα treated cells. All other differences are not statistically significant (P>0.05). 
 
Annex:  Acceptance Information 
 
 
 
01-Aug-2017 
 
Dear Professor Trayhurn: 
 
Ref: IL-1β and TNFα inhibit GPR120 (<i>FFAR4</i>) and stimulate GPR84 
(<i>EX33</i>) and GPR41 (<i>FFAR3</i>) fatty acid receptor expression in 
human adipocytes: implications for the anti-inflammatory action of n-3 
fatty acids 
 
Our referees have now considered your paper and have recommended 
publication in Archives Of Physiology And Biochemistry.  We are pleased to 
accept your paper in its current form which will now be forwarded to the 
publisher for copy editing and typesetting. The reviewer comments are 
included at the bottom of this letter. 
 
You will receive proofs for checking, and instructions for transfer of 
copyright in due course. 
 
The publisher also requests that proofs are checked and returned within 48 
hours of receipt. 
 
Thank you for your contribution to Archives Of Physiology And Biochemistry 
and we look forward to receiving further submissions from you. 
 
 
Sincerely, 
Dr Eckel 
Editor in Chief, Archives Of Physiology And Biochemistry 
 
eckel@uni-duesseldorf.de 
 
 
